National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

A review of the economic evaluation of oral gefitinib (Iressa®) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
16/06/2010 05/11/2010  

We do not recommend the reimbursement of gefitinib for first line therapy on the High Tech Drug Scheme.  However, it may be considered for second line therapy.

Gefitinib (Iressa®) Summary